Have a feature idea you'd love to see implemented?
Let us know!
TNXP Tonix Pharmaceuticals Holding Corp
Price (delayed)
$0.2042
Market cap
$38.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.67
Enterprise value
$18.62M
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's
Highlights
TNXP's EPS has soared by 97% YoY and by 83% from the previous quarter
The debt has declined by 6% since the previous quarter
The company's revenue has surged by 183% YoY but it fell by 9% QoQ
The company's equity has surged by 76% QoQ but it fell by 39% YoY
TNXP's gross margin is down by 49% YoY and by 4.2% from the previous quarter
Key stats
What are the main financial stats of TNXP
Market
Valuations
Earnings
Shares outstanding
186.89M
Market cap
$38.16M
Enterprise value
$18.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.06
Price to sales (P/S)
1.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.65
Revenue
$11.29M
EBIT
-$135.25M
EBITDA
-$131.06M
Free cash flow
-$69.18M
Per share
Balance sheet
Liquidity
EPS
-$7.67
Free cash flow per share
-$1.11
Book value per share
$3.37
Revenue per share
$0.18
TBVPS
$1.53
Total assets
$94.99M
Total liabilities
$20.78M
Debt
$8.69M
Equity
$74.21M
Working capital
$35.36M
Debt to equity
0.12
Current ratio
3.33
Quick ratio
2.12
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-1,160.8%
Gross margin
20.7%
Net margin
-1,197.9%
Operating margin
-1,253.7%
Return on assets
-118.9%
Return on equity
-163.9%
Return on invested capital
-163.8%
Return on capital employed
-169.5%
Return on sales
-1,197.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNXP stock price
How has the Tonix Pharmaceuticals Holding stock price performed over time
Intraday
7.47%
1 week
45.86%
1 month
7.53%
1 year
-98.7%
YTD
-98.42%
QTD
37.51%
Financial performance
How have Tonix Pharmaceuticals Holding's revenue and profit performed over time
Revenue
$11.29M
Gross profit
$2.34M
Operating income
-$141.55M
Net income
-$135.25M
Gross margin
20.7%
Net margin
-1,197.9%
The company's revenue has surged by 183% YoY but it fell by 9% QoQ
The net margin has surged by 61% year-on-year
Tonix Pharmaceuticals Holding's operating margin has soared by 60% YoY
TNXP's gross margin is down by 49% YoY and by 4.2% from the previous quarter
Growth
What is Tonix Pharmaceuticals Holding's growth rate over time
Valuation
What is Tonix Pharmaceuticals Holding stock price valuation
P/E
N/A
P/B
0.06
P/S
1.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.65
TNXP's EPS has soared by 97% YoY and by 83% from the previous quarter
The P/B is 90% lower than the 5-year quarterly average of 0.6 and 40% lower than the last 4 quarters average of 0.1
The company's equity has surged by 76% QoQ but it fell by 39% YoY
The company's revenue has surged by 183% YoY but it fell by 9% QoQ
TNXP's P/S is 40% above its last 4 quarters average of 0.8
Efficiency
How efficient is Tonix Pharmaceuticals Holding business performance
The company's return on equity has shrunk by 110% YoY and by 3.5% QoQ
TNXP's ROA has shrunk by 70% YoY
TNXP's ROS has soared by 61% YoY
TNXP's return on invested capital is down by 33% year-on-year and by 3% since the previous quarter
Dividends
What is TNXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNXP.
Financial health
How did Tonix Pharmaceuticals Holding financials performed over time
The current ratio has surged by 190% since the previous quarter and by 88% year-on-year
The total assets has grown by 35% from the previous quarter but it has contracted by 32% YoY
The debt is 88% smaller than the equity
The company's equity has surged by 76% QoQ but it fell by 39% YoY
The debt to equity has contracted by 45% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.